Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

iRadimed (IRMD) Financials

iRadimed logo
$72.46 -0.56 (-0.77%)
As of 01:07 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for iRadimed

Annual Income Statements for iRadimed

This table shows iRadimed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 2.05 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19
Consolidated Net Income / (Loss)		 2.05 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19
Net Income / (Loss) Continuing Operations		 2.05 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19
Total Pre-Tax Income 		3.02 12 11 1.40 6.20 9.04 -0.62 9.84 16 22 24
Total Operating Income		 3.07 12 11 1.29 6.00 8.65 -0.76 9.82 16 20 22
Total Gross Profit		 12 26 26 18 23 30 24 32 41 50 56
Total Revenue		 16 32 32 23 30 39 32 42 53 66 73
Operating Revenue		 16 32 32 23 30 39 32 42 53 66 73
Total Cost of Revenue		 3.40 5.84 6.15 5.57 7.21 8.82 8.14 9.76 12 15 17
Operating Cost of Revenue		 3.40 5.84 6.15 5.57 7.21 8.82 8.14 9.76 12 15 17
Total Operating Expenses		 9.18 14 15 16 17 21 24 22 26 30 34
Selling, General & Admin Expense		 4.82 7.77 8.80 9.00 8.71 10 12 9.77 11 15 16
Marketing Expense		 3.30 4.71 5.28 5.50 7.00 9.17 10 11 13 12 16
Research & Development Expense		 1.07 1.76 1.35 1.72 1.52 1.43 1.90 1.91 2.28 2.86 2.83
Total Other Income / (Expense), net		 -0.05 0.12 0.03 0.11 0.19 0.40 0.14 0.02 0.55 1.70 2.31
Other Income / (Expense), net		 -0.05 0.12 0.03 0.11 0.19 0.40 0.14 0.02 0.55 1.70 2.31
Income Tax Expense		 0.97 4.10 3.74 0.90 -0.11 -0.59 -1.99 0.51 3.35 4.55 5.04
Basic Earnings per Share		 $0.23 $0.68 $0.67 $0.05 $0.59 $0.85 $0.11 $0.76 $1.02 $1.36 $1.52
Weighted Average Basic Shares Outstanding		 8.74M 11.00M 10.82M 10.64M 10.76M 11.28M 12.12M 12.35M 12.56M 12.60M 12.67M
Diluted Earnings per Share		 $0.20 $0.60 $0.60 $0.04 $0.52 $0.78 $0.11 $0.74 $1.02 $1.35 $1.50
Weighted Average Diluted Shares Outstanding		 10.22M 12.56M 11.99M 11.72M 12.11M 12.28M 12.44M 12.59M 12.64M 12.72M 12.78M
Weighted Average Basic & Diluted Shares Outstanding		 8.90M 11.10M 10.80M 10M 11.00M 11.92M 12.31M 12.56M 12.59M 12.66M 12.72M

Quarterly Income Statements for iRadimed

This table shows iRadimed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 3.67 3.41 4.18 5.07 4.54 4.14 4.90 5.05 5.15 4.69 5.77
Consolidated Net Income / (Loss)		 3.67 3.41 4.18 5.07 4.54 4.14 4.90 5.05 5.15 4.69 5.77
Net Income / (Loss) Continuing Operations		 3.67 3.41 4.18 5.07 4.54 4.14 4.90 5.05 5.15 4.69 5.77
Total Pre-Tax Income 		4.70 4.35 5.30 6.41 5.68 5.24 6.27 6.42 6.34 5.95 7.33
Total Operating Income		 4.25 4.01 4.96 5.91 5.16 4.75 5.63 5.79 5.80 5.43 6.79
Total Gross Profit		 11 12 12 13 13 13 14 14 15 15 16
Total Revenue		 15 15 16 17 17 18 18 18 19 20 20
Operating Revenue		 15 15 16 17 17 18 18 18 19 20 20
Total Cost of Revenue		 3.64 3.75 3.94 3.67 4.04 4.21 3.92 4.13 4.63 4.67 4.45
Operating Cost of Revenue		 3.64 3.75 3.94 3.67 4.04 4.21 3.92 4.13 4.63 4.67 4.45
Total Operating Expenses		 6.97 7.71 7.22 6.93 8.25 8.64 8.38 8.40 8.96 9.41 9.17
Selling, General & Admin Expense		 2.70 3.92 3.31 3.62 4.27 3.99 4.10 3.97 3.87 4.61 4.28
Marketing Expense		 3.67 0.79 2.95 2.86 5.54 3.83 3.48 3.80 7.52 4.18 4.01
Research & Development Expense		 0.60 3.00 0.96 0.45 -1.56 0.82 0.80 0.64 -2.44 0.62 0.88
Total Other Income / (Expense), net		 0.45 0.34 0.34 0.50 0.52 0.50 0.64 0.63 0.54 0.51 0.54
Other Income / (Expense), net		 0.45 0.34 0.34 0.50 0.52 0.50 0.64 0.63 0.54 0.51 0.54
Income Tax Expense		 1.03 0.94 1.12 1.34 1.14 1.11 1.37 1.37 1.20 1.26 1.55
Basic Earnings per Share		 $0.29 $0.27 $0.33 $0.40 $0.36 $0.33 $0.39 $0.40 $0.40 $0.37 $0.45
Weighted Average Basic Shares Outstanding		 12.56M 12.59M 12.60M 12.60M 12.60M 12.66M 12.66M 12.67M 12.67M 12.71M 12.72M
Diluted Earnings per Share		 $0.29 $0.27 $0.33 $0.40 $0.35 $0.32 $0.38 $0.40 $0.40 $0.37 $0.45
Weighted Average Diluted Shares Outstanding		 12.64M 12.69M 12.72M 12.74M 12.72M 12.75M 12.76M 12.78M 12.78M 12.83M 12.84M
Weighted Average Basic & Diluted Shares Outstanding		 12.59M 12.59M 12.60M 12.61M 12.66M 12.66M 12.67M 12.67M 12.72M 12.72M 12.72M

Annual Cash Flow Statements for iRadimed

This table details how cash moves in and out of iRadimed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 6.99 9.91 -1.65 0.49 9.82 15 6.59 12 -4.04 -8.20 2.47
Net Cash From Operating Activities		 2.92 7.65 9.41 3.42 7.38 10 5.82 11 10 13 26
Net Cash From Continuing Operating Activities		 2.59 7.65 9.41 3.42 7.38 10 5.82 11 10 13 26
Net Income / (Loss) Continuing Operations		 2.05 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19
Consolidated Net Income / (Loss)		 2.05 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19
Depreciation Expense		 0.15 0.81 0.96 1.31 1.11 1.24 1.34 1.41 0.67 0.77 0.82
Non-Cash Adjustments To Reconcile Net Income		 0.69 1.34 2.04 2.75 1.93 1.93 3.90 1.62 1.59 2.61 2.52
Changes in Operating Assets and Liabilities, net		 -0.30 -2.03 -0.80 -1.14 -1.97 -2.57 -0.79 -1.07 -5.02 -7.11 3.05
Net Cash From Investing Activities		 -8.30 -0.06 -1.94 -1.02 1.52 3.20 0.25 0.65 -1.37 -8.01 -8.82
Net Cash From Continuing Investing Activities		 -8.30 -0.06 -1.94 -1.02 1.52 3.20 0.25 0.65 -1.37 -8.01 -8.82
Purchase of Property, Plant & Equipment		 -0.61 -0.31 -1.52 -0.82 -0.26 -0.49 -0.64 -0.74 -1.87 -8.01 -8.82
Net Cash From Financing Activities		 13 2.33 -9.12 -1.90 0.93 2.02 0.52 0.02 -13 -14 -14
Net Cash From Continuing Financing Activities		 13 2.33 -9.12 -1.90 0.93 2.02 0.52 0.02 -13 -14 -14
Payment of Dividends		 - - - - - - - 0.00 -13 -13 -14
Other Financing Activities, net		 0.17 1.73 0.60 -0.16 0.93 -0.47 -1.21 0.02 -0.15 -0.43 -0.66
Cash Income Taxes Paid		 1.18 2.70 3.39 1.21 1.38 0.01 0.00 0.97 1.71 5.35 6.51

Quarterly Cash Flow Statements for iRadimed

This table details how cash moves in and out of iRadimed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Change in Cash & Equivalents		 2.37 -15 3.05 0.92 3.02 -4.64 3.41 3.19 0.51 -1.90 2.66
Net Cash From Operating Activities		 3.04 4.65 3.51 1.39 3.91 3.88 6.64 9.12 5.99 4.29 7.75
Net Cash From Continuing Operating Activities		 3.06 4.65 3.51 1.39 3.91 3.88 6.64 9.03 6.08 4.29 7.75
Net Income / (Loss) Continuing Operations		 3.67 3.41 4.18 5.07 4.54 4.14 4.90 5.05 5.15 4.69 5.77
Consolidated Net Income / (Loss)		 3.67 3.41 4.18 5.07 4.54 4.14 4.90 5.05 5.15 4.69 5.77
Depreciation Expense		 -0.69 0.18 0.19 0.19 0.21 0.23 0.20 0.20 0.19 0.19 0.21
Non-Cash Adjustments To Reconcile Net Income		 0.56 0.81 0.65 0.57 0.59 0.63 0.74 0.02 1.13 0.77 0.76
Changes in Operating Assets and Liabilities, net		 -0.48 0.25 -1.50 -4.43 -1.42 -1.11 0.80 3.75 -0.40 -1.36 1.00
Net Cash From Investing Activities		 -0.47 -6.56 -0.38 -0.44 -0.63 -0.48 -1.27 -4.01 -3.06 -3.92 -2.82
Net Cash From Continuing Investing Activities		 -0.47 -6.56 -0.38 -0.44 -0.63 -0.48 -1.27 -4.01 -3.06 -3.92 -2.82
Purchase of Property, Plant & Equipment		 -0.47 -6.56 -0.38 -0.44 -0.63 -0.48 -1.27 -4.01 -3.06 -3.92 -2.82
Net Cash From Financing Activities		 -0.20 -13 -0.09 -0.03 -0.26 -8.04 -1.96 -1.92 -2.42 -2.28 -2.26
Net Cash From Continuing Financing Activities		 -0.20 -13 -0.09 -0.03 -0.26 -8.04 -1.96 -1.92 -2.42 -2.28 -2.26
Payment of Dividends		 - -13 - - - -7.98 -1.90 -1.90 -1.90 -2.16 -2.16
Other Financing Activities, net		 -0.20 -0.05 -0.09 -0.03 -0.26 -0.06 -0.06 -0.02 -0.52 -0.12 -0.10
Cash Income Taxes Paid		 0.95 0.00 2.76 1.38 1.22 0.19 2.82 1.45 2.06 0.01 2.34

Annual Balance Sheets for iRadimed

This table presents iRadimed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 23 35 37 39 48 67 71 83 86 92 98
Total Current Assets		 22 34 34 35 45 59 64 76 77 76 75
Cash & Equivalents		 9.45 19 18 18 28 43 50 62 58 50 52
Accounts Receivable		 1.96 3.86 3.78 3.78 4.21 7.29 4.57 5.14 13 12 11
Inventories, net		 2.13 2.38 3.89 4.21 4.06 3.64 3.93 4.30 5.37 13 10
Prepaid Expenses		 0.28 0.32 0.36 0.65 0.53 0.41 0.77 1.00 0.63 1.19 1.51
Current Deferred & Refundable Income Taxes		 0.44 0.42 0.15 0.13 1.37 1.37 2.48 3.31 0.25 - 0.54
Plant, Property, & Equipment, net		 0.79 0.91 1.46 1.87 1.87 2.05 2.12 2.07 2.40 9.29 17
Total Noncurrent Assets		 0.35 0.39 1.88 2.04 2.03 5.71 5.21 4.57 5.62 6.87 6.27
Intangible Assets		 0.25 0.19 0.92 0.89 0.83 0.86 0.96 1.12 2.07 2.52 3.10
Noncurrent Deferred & Refundable Income Taxes		 0.08 0.09 0.79 0.95 1.09 1.66 1.27 0.77 0.70 2.12 2.82
Other Noncurrent Operating Assets		 0.02 0.10 0.17 0.20 0.11 3.19 2.98 2.68 2.85 2.22 0.35
Total Liabilities & Shareholders' Equity		 23 35 37 39 48 67 71 83 86 92 98
Total Liabilities		 2.42 3.31 5.31 6.08 6.50 11 9.68 11 12 21 12
Total Current Liabilities		 2.28 2.89 3.66 4.08 4.69 5.86 4.92 6.82 8.55 16 8.51
Accounts Payable		 0.63 1.01 1.12 0.66 0.77 0.99 0.66 0.78 1.80 1.86 1.90
Accrued Expenses		 0.03 0.03 0.04 0.06 0.07 0.08 0.09 0.11 0.09 0.12 0.12
Current Deferred Revenue		 0.31 0.53 1.03 1.62 1.80 1.67 1.95 2.55 3.37 2.57 2.26
Current Employee Benefit Liabilities		 1.24 1.29 1.04 1.51 1.80 2.17 1.71 2.81 2.87 2.78 3.77
Other Taxes Payable		 0.07 0.03 0.12 0.11 0.13 0.60 0.10 0.14 0.12 0.10 0.16
Other Current Liabilities		 - - 0.12 0.11 0.11 0.35 0.40 0.42 0.29 0.68 0.30
Total Noncurrent Liabilities		 0.14 0.42 1.64 2.00 1.81 5.35 4.76 3.88 3.29 4.41 2.99
Noncurrent Deferred Revenue		 0.14 0.42 1.64 2.00 1.81 2.63 2.31 1.68 1.38 2.79 2.99
Other Noncurrent Operating Liabilities		 - - - - - 2.72 2.46 2.21 1.91 1.62 0.00
Total Equity & Noncontrolling Interests		 21 32 32 33 42 56 61 72 74 71 87
Total Preferred & Common Equity		 21 32 32 33 42 56 61 72 74 71 87
Total Common Equity		 21 32 32 33 42 56 61 72 74 71 87
Common Stock		 16 19 12 13 15 19 24 25 26 28 30
Retained Earnings		 5.13 13 20 20 27 36 38 47 47 43 57

Quarterly Balance Sheets for iRadimed

This table presents iRadimed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025
Total Assets		 76 80 76 81 87 88 90 94 102 106
Total Current Assets		 68 72 61 66 72 72 74 74 75 77
Cash & Equivalents		 52 56 43 46 47 45 49 52 50 53
Accounts Receivable		 8.38 11 12 11 13 13 12 10 13 11
Inventories, net		 4.86 5.24 6.31 8.42 12 13 12 11 11 11
Prepaid Expenses		 0.80 0.39 0.68 0.77 0.74 1.04 1.02 0.95 1.54 1.92
Current Deferred & Refundable Income Taxes		 2.30 0.00 0.00 0.00 0.00 - - - - 0.33
Plant, Property, & Equipment, net		 2.24 2.29 8.64 8.72 8.89 9.45 10 14 20 23
Total Noncurrent Assets		 4.99 5.38 5.68 6.62 6.59 6.68 5.90 5.80 6.21 6.14
Intangible Assets		 1.54 1.88 2.21 2.35 2.46 2.67 2.75 2.89 3.26 3.37
Noncurrent Deferred & Refundable Income Taxes		 0.90 0.99 0.62 1.77 1.80 1.88 2.59 2.46 2.69 2.56
Other Noncurrent Operating Assets		 2.55 2.51 2.85 2.50 2.32 2.12 0.56 0.45 0.27 0.20
Total Liabilities & Shareholders' Equity		 76 80 76 81 87 88 90 94 102 106
Total Liabilities		 9.83 9.77 11 12 13 12 10 11 12 12
Total Current Liabilities		 6.14 5.60 6.76 7.59 7.88 7.62 7.46 8.06 8.47 8.81
Accounts Payable		 0.82 0.96 1.76 2.55 2.78 1.29 1.12 1.40 2.59 1.90
Accrued Expenses		 0.10 0.10 0.10 0.11 0.11 0.12 0.12 0.12 0.12 0.12
Current Deferred Revenue		 2.29 1.59 2.07 1.71 1.92 2.34 2.54 2.56 2.60 3.26
Current Employee Benefit Liabilities		 2.27 2.35 1.62 2.33 2.29 2.14 2.90 3.28 2.27 3.21
Other Taxes Payable		 0.24 0.18 0.06 0.22 0.10 0.14 0.16 0.19 0.26 0.32
Other Current Liabilities		 0.42 0.43 0.66 0.66 0.67 0.67 0.62 0.51 0.06 0.00
Total Noncurrent Liabilities		 3.69 4.17 4.52 4.85 4.96 4.28 2.82 2.75 3.20 3.33
Noncurrent Deferred Revenue		 1.63 2.18 2.59 3.01 3.23 2.76 2.82 2.75 3.20 3.33
Other Noncurrent Operating Liabilities		 2.06 1.99 1.94 1.83 1.72 1.52 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 66 70 64 69 75 76 80 83 90 94
Total Preferred & Common Equity		 66 70 64 69 75 76 80 83 90 94
Total Common Equity		 66 70 64 69 75 76 80 83 90 94
Common Stock		 26 26 27 27 28 29 29 30 31 31
Retained Earnings		 40 44 37 42 47 47 50 54 59 63

Annual Metrics And Ratios for iRadimed

This table displays calculated financial ratios and metrics derived from iRadimed's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 38.03% 101.84% 2.86% -28.97% 31.88% 26.54% -17.65% 31.83% 27.48% 23.00% 11.71%
EBITDA Growth		 8.33% 292.93% -4.29% -77.28% 169.94% 40.85% -92.98% 1,457.33% 49.88% 33.54% 11.51%
EBIT Growth		 8.39% 285.59% -5.86% -87.25% 343.81% 45.92% -106.82% 1,694.53% 64.50% 34.35% 11.67%
NOPAT Growth		 7.43% 257.66% -3.47% -93.61% 1,227.80% 50.81% -105.75% 1,858.64% 33.11% 27.89% 9.83%
Net Income Growth		 5.86% 267.25% -4.19% -93.07% 1,161.29% 52.79% -85.79% 581.19% 37.56% 34.02% 11.87%
EPS Growth		 -9.09% 200.00% 0.00% -93.33% 1,200.00% 50.00% -85.90% 572.73% 37.84% 32.35% 11.11%
Operating Cash Flow Growth		 97.79% 162.31% 22.97% -63.68% 115.93% 38.73% -43.15% 93.52% -10.80% 34.08% 90.30%
Free Cash Flow Firm Growth		 0.00% 368.92% -1.09% -98.66% 6,321.75% 46.31% -108.82% 1,466.98% -29.77% -69.70% 547.14%
Invested Capital Growth		 29.45% 40.88% 25.13% 6.12% 14.85% 22.54% 1.43% 2.83% 62.44% 88.61% 16.71%
Revenue Q/Q Growth		 0.00% 19.77% -7.96% 3.20% 5.67% 7.09% -6.88% 8.64% 5.94% 4.11% 2.72%
EBITDA Q/Q Growth		 0.00% 42.97% -15.59% -12.63% 11.72% 5.10% -69.32% 28.54% 3.12% 9.10% 2.67%
EBIT Q/Q Growth		 0.00% 37.05% -14.12% -25.70% 15.77% 5.58% -157.50% 33.15% 10.90% 4.71% 2.81%
NOPAT Q/Q Growth		 0.00% 39.78% -15.25% -66.86% 31.24% 18.79% -117.18% 53.92% -4.34% 5.33% 3.46%
Net Income Q/Q Growth		 0.00% 39.55% -14.91% -65.70% 31.87% 18.96% -65.54% 53.63% -1.68% 5.30% 3.26%
EPS Q/Q Growth		 0.00% 39.53% -13.04% -66.67% 33.33% 18.18% -65.63% 54.17% -1.92% 4.65% 3.45%
Operating Cash Flow Q/Q Growth		 -31.46% 22.04% 17.68% -19.41% 40.90% 4.14% -19.98% 8.37% -3.16% 6.94% 8.81%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -6.42% -93.79% 91.61% 0.72% -155.53% 5.50% -13.57% 37.40% -3.72%
Invested Capital Q/Q Growth		 0.00% 5.73% -9.04% -4.90% -15.02% 0.71% -15.24% 12.80% 10.81% 6.51% 9.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 78.25% 81.51% 81.06% 75.87% 76.31% 77.11% 74.33% 76.65% 77.45% 76.50% 76.94%
EBITDA Margin		 20.23% 39.38% 36.65% 11.72% 23.99% 26.70% 2.28% 26.89% 31.61% 34.32% 34.26%
Operating Margin		 19.59% 36.44% 33.60% 5.57% 19.72% 22.45% -2.38% 23.48% 29.32% 30.56% 29.99%
EBIT Margin		 19.28% 36.83% 33.70% 6.05% 20.36% 23.48% -1.94% 23.52% 30.36% 33.16% 33.14%
Profit (Net Income) Margin		 13.10% 23.83% 22.20% 2.17% 20.71% 25.00% 4.32% 22.30% 24.07% 26.22% 26.26%
Tax Burden Percent		 67.95% 64.72% 65.87% 35.79% 101.71% 106.50% -221.92% 94.81% 79.28% 79.09% 79.23%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 32.05% 35.28% 34.13% 64.21% -1.71% -6.50% 0.00% 5.19% 20.72% 20.91% 20.77%
Return on Invested Capital (ROIC)		 66.73% 175.63% 128.76% 7.19% 86.26% 109.36% -5.67% 97.57% 97.62% 69.89% 54.20%
ROIC Less NNEP Spread (ROIC-NNEP)		 67.06% 175.27% 128.68% 7.03% 85.62% 108.31% -9.53% 97.54% 96.89% 67.19% 50.31%
Return on Net Nonoperating Assets (RNNOA)		 -51.15% -147.12% -106.16% -5.64% -69.43% -89.60% 8.01% -83.61% -80.03% -46.19% -29.89%
Return on Equity (ROE)		 15.58% 28.51% 22.61% 1.54% 16.84% 19.76% 2.34% 13.96% 17.59% 23.70% 24.31%
Cash Return on Invested Capital (CROIC)		 41.06% 141.69% 106.44% 1.25% 72.44% 89.10% -7.08% 94.78% 50.03% 8.49% 38.78%
Operating Return on Assets (OROA)		 19.92% 39.74% 30.24% 3.66% 14.17% 15.70% -0.90% 12.78% 19.22% 24.47% 25.49%
Return on Assets (ROA)		 13.54% 25.72% 19.92% 1.31% 14.42% 16.72% 1.99% 12.12% 15.24% 19.35% 20.20%
Return on Common Equity (ROCE)		 15.58% 28.51% 22.61% 1.54% 16.84% 19.76% 2.34% 13.96% 17.59% 23.70% 24.31%
Return on Equity Simple (ROE_SIMPLE)		 9.81% 23.58% 22.62% 1.52% 15.03% 17.35% 2.23% 12.92% 17.41% 24.07% 22.15%
Net Operating Profit after Tax (NOPAT)		 2.08 7.45 7.19 0.46 6.11 9.21 -0.53 9.31 12 16 17
NOPAT Margin		 13.31% 23.58% 22.13% 1.99% 20.06% 23.91% -1.67% 22.26% 23.24% 24.17% 23.76%
Net Nonoperating Expense Percent (NNEP)		 -0.33% 0.35% 0.08% 0.15% 0.65% 1.05% 3.87% 0.03% 0.73% 2.70% 3.89%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - 22.19% 20.05%
Cost of Revenue to Revenue		 21.75% 18.49% 18.94% 24.13% 23.69% 22.89% 25.67% 23.35% 22.55% 23.50% 23.06%
SG&A Expenses to Revenue		 30.77% 24.59% 27.07% 39.00% 28.62% 27.13% 38.68% 23.37% 20.07% 23.07% 21.76%
R&D to Revenue		 6.83% 5.58% 4.15% 7.46% 4.98% 3.72% 6.00% 4.56% 4.27% 4.36% 3.87%
Operating Expenses to Revenue		 58.66% 45.07% 47.46% 70.30% 56.58% 54.66% 76.71% 53.17% 48.13% 45.95% 46.95%
Earnings before Interest and Taxes (EBIT)		 3.02 12 11 1.40 6.20 9.04 -0.62 9.84 16 22 24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 3.17 12 12 2.71 7.30 10 0.72 11 17 23 25
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.22 9.05 3.47 4.52 5.94 4.50 4.24 7.36 4.59 8.27 8.00
Price to Tangible Book Value (P/TBV)		 6.29 9.10 3.58 4.65 6.06 4.57 4.31 7.47 4.72 8.58 8.30
Price to Revenue (P/Rev)		 8.30 9.15 3.41 6.45 8.18 6.49 8.21 12.70 6.34 9.01 9.49
Price to Earnings (P/E)		 63.36 38.37 15.35 297.98 39.51 25.96 190.30 56.95 26.33 34.37 36.13
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.72% 3.26% 1.70%
Earnings Yield		 1.58% 2.61% 6.52% 0.34% 2.53% 3.85% 0.53% 1.76% 3.80% 2.91% 2.77%
Enterprise Value to Invested Capital (EV/IC)		 31.95 52.79 13.70 18.60 28.37 21.97 22.17 48.45 17.81 18.26 18.58
Enterprise Value to Revenue (EV/Rev)		 7.19 8.29 2.62 5.31 7.05 5.29 6.57 11.21 5.25 8.25 8.78
Enterprise Value to EBITDA (EV/EBITDA)		 35.55 21.06 7.14 45.31 29.40 19.81 288.85 41.68 16.61 24.04 25.61
Enterprise Value to EBIT (EV/EBIT)		 37.30 22.52 7.77 87.78 34.64 22.54 0.00 47.64 17.30 24.89 26.48
Enterprise Value to NOPAT (EV/NOPAT)		 54.02 35.16 11.82 266.53 35.16 22.13 0.00 50.35 22.59 34.15 36.93
Enterprise Value to Operating Cash Flow (EV/OCF)		 38.60 34.25 9.04 35.88 29.11 19.92 35.85 41.62 27.87 40.18 25.08
Enterprise Value to Free Cash Flow (EV/FCFF)		 87.80 43.58 14.30 1,534.96 41.86 27.16 0.00 51.83 44.07 281.19 51.61
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.76 -0.84 -0.82 -0.80 -0.81 -0.83 -0.84 -0.86 -0.83 -0.69 -0.59
Leverage Ratio		 1.15 1.11 1.14 1.18 1.17 1.18 1.18 1.15 1.15 1.22 1.20
Compound Leverage Factor		 1.15 1.11 1.14 1.18 1.17 1.18 1.18 1.15 1.15 1.22 1.20
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 34.65 55.90 16.09 17.09 25.81 16.13 18.30 32.46 20.11 20.02 39.42
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.74 11.76 9.25 8.61 9.50 10.06 12.96 11.18 9.06 4.65 8.84
Quick Ratio		 8.49 10.68 8.04 7.39 8.23 9.14 11.50 9.91 8.33 3.80 7.38
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 1.28 6.01 5.95 0.08 5.13 7.50 -0.66 9.04 6.35 1.92 12
Operating Cash Flow to CapEx		 480.99% 2,429.60% 617.09% 414.17% 2,786.93% 2,106.32% 913.63% 1,517.76% 535.61% 168.16% 290.63%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.03 1.08 0.90 0.61 0.70 0.67 0.46 0.54 0.63 0.74 0.77
Accounts Receivable Turnover		 7.94 10.85 8.51 6.11 7.62 6.70 5.34 8.61 5.79 5.14 6.43
Inventory Turnover		 1.96 2.59 1.96 1.38 1.74 2.29 2.15 2.37 2.49 1.69 1.45
Fixed Asset Turnover		 27.90 37.16 27.52 13.88 16.28 19.63 15.20 19.96 23.85 11.22 5.61
Accounts Payable Turnover		 6.44 7.15 5.79 6.27 10.09 9.98 9.87 13.56 9.31 8.43 9.00
Days Sales Outstanding (DSO)		 45.96 33.64 42.90 59.73 47.90 54.50 68.29 42.39 63.04 70.98 56.76
Days Inventory Outstanding (DIO)		 185.81 140.90 185.91 265.32 209.29 159.42 169.78 153.89 146.80 215.51 250.90
Days Payable Outstanding (DPO)		 56.64 51.08 63.05 58.24 36.17 36.56 37.00 26.91 39.20 43.32 40.55
Cash Conversion Cycle (CCC)		 175.13 123.46 165.76 266.81 221.02 177.36 201.07 169.36 170.63 243.17 267.11
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 3.52 4.96 6.21 6.59 7.57 9.27 9.41 9.67 16 30 35
Invested Capital Turnover		 5.01 7.45 5.82 3.61 4.30 4.57 3.40 4.38 4.20 2.89 2.28
Increase / (Decrease) in Invested Capital		 0.80 1.44 1.25 0.38 0.98 1.71 0.13 0.27 6.04 14 4.95
Enterprise Value (EV)		 113 262 85 123 215 204 209 469 280 541 643
Market Capitalization		 130 289 111 149 249 250 261 531 338 591 695
Book Value per Share		 $1.93 $2.88 $2.98 $3.12 $3.84 $4.83 $5.00 $5.85 $5.86 $5.67 $6.85
Tangible Book Value per Share		 $1.91 $2.87 $2.89 $3.04 $3.76 $4.76 $4.92 $5.76 $5.70 $5.47 $6.61
Total Capital		 21 32 32 33 42 56 61 72 74 71 87
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -17 -27 -26 -26 -34 -46 -52 -63 -58 -50 -52
Capital Expenditures (CapEx)		 0.61 0.31 1.52 0.82 0.26 0.49 0.64 0.74 1.87 8.01 8.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2.52 4.09 4.52 4.69 5.47 6.85 6.84 6.92 11 9.91 14
Debt-free Net Working Capital (DFNWC)		 20 31 30 31 40 53 59 69 69 60 67
Net Working Capital (NWC)		 20 31 30 31 40 53 59 69 69 60 67
Net Nonoperating Expense (NNE)		 0.03 -0.08 -0.02 -0.04 -0.20 -0.42 -1.90 -0.02 -0.44 -1.35 -1.83
Net Nonoperating Obligations (NNO)		 -17 -27 -26 -26 -34 -46 -52 -63 -58 -42 -52
Total Depreciation and Amortization (D&A)		 0.15 0.81 0.96 1.31 1.11 1.24 1.34 1.41 0.67 0.77 0.82
Debt-free, Cash-free Net Working Capital to Revenue		 16.12% 12.96% 13.89% 20.31% 17.99% 17.80% 21.57% 16.55% 20.59% 15.12% 19.79%
Debt-free Net Working Capital to Revenue		 127.08% 98.33% 92.92% 134.43% 130.92% 137.87% 185.45% 166.02% 129.33% 91.02% 91.11%
Net Working Capital to Revenue		 127.08% 98.33% 92.92% 134.43% 130.92% 137.87% 185.45% 166.02% 129.33% 91.02% 91.11%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.23 $0.68 $0.67 $0.05 $0.59 $0.85 $0.11 $0.76 $1.02 $1.36 $1.52
Adjusted Weighted Average Basic Shares Outstanding		 8.74M 11.00M 10.82M 10.64M 10.76M 11.28M 12.12M 12.35M 12.56M 12.60M 12.67M
Adjusted Diluted Earnings per Share		 $0.20 $0.60 $0.60 $0.04 $0.52 $0.78 $0.11 $0.74 $1.02 $1.35 $1.50
Adjusted Weighted Average Diluted Shares Outstanding		 10.22M 12.56M 11.99M 11.72M 12.11M 12.28M 12.44M 12.59M 12.64M 12.72M 12.78M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 10.97M 11.03M 10.74M 10.60M 11.00M 11.92M 12.31M 12.56M 12.59M 12.66M 12.72M
Normalized Net Operating Profit after Tax (NOPAT)		 2.08 7.45 7.19 0.90 4.20 6.05 -0.53 9.31 12 16 17
Normalized NOPAT Margin		 13.31% 23.58% 22.13% 3.90% 13.81% 15.72% -1.67% 22.26% 23.24% 24.17% 23.76%
Pre Tax Income Margin		 19.28% 36.83% 33.70% 6.05% 20.36% 23.48% -1.94% 23.52% 30.36% 33.16% 33.14%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 97.90% 76.91% 71.11%
Augmented Payout Ratio		 99.71% 0.00% 138.19% 363.88% 0.00% 0.00% 0.00% 0.00% 97.90% 76.91% 71.11%

Quarterly Metrics And Ratios for iRadimed

This table displays calculated financial ratios and metrics derived from iRadimed's official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 25.19% 25.70% 26.80% 23.10% 17.42% 13.72% 11.15% 11.04% 11.10% 10.87% 13.84%
EBITDA Growth		 14.59% 29.72% 17.37% 41.20% 46.78% 20.68% 17.91% 0.26% 11.08% 12.25% 16.49%
EBIT Growth		 51.07% 42.15% 26.77% 51.23% 20.79% 20.55% 18.32% 0.15% 11.66% 13.39% 16.88%
NOPAT Growth		 -14.54% 25.58% 21.18% 39.71% 24.09% 19.38% 12.36% -2.46% 14.13% 14.32% 21.59%
Net Income Growth		 -5.63% 36.97% 28.97% 47.86% 23.58% 21.45% 17.26% -0.35% 13.37% 13.32% 17.81%
EPS Growth		 -6.45% 35.00% 26.92% 48.15% 20.69% 18.52% 15.15% 0.00% 14.29% 15.63% 18.42%
Operating Cash Flow Growth		 -9.72% 225.77% 114.36% -64.64% 28.75% -16.42% 88.93% 554.54% 53.02% 10.53% 16.69%
Free Cash Flow Firm Growth		 -175.03% -637.03% -221.50% -296.70% -260.61% 16.66% 35.47% 107.42% 97.49% 21.80% -35.34%
Invested Capital Growth		 62.44% 85.86% 68.66% 96.22% 88.61% 43.74% 34.35% 13.98% 16.71% 28.16% 32.66%
Revenue Q/Q Growth		 10.86% 4.11% 4.23% 2.32% 5.74% 0.84% 1.88% 2.21% 5.80% 0.63% 4.61%
EBITDA Q/Q Growth		 -14.17% 13.00% 21.04% 20.28% -10.78% -7.09% 18.26% 2.28% -1.16% -6.11% 22.72%
EBIT Q/Q Growth		 11.00% -7.52% 21.81% 20.95% -11.34% -7.71% 19.56% 2.38% -1.15% -6.29% 23.24%
NOPAT Q/Q Growth		 -0.59% -5.55% 24.77% 19.26% -11.71% -9.14% 17.44% 3.53% 3.31% -8.99% 24.91%
Net Income Q/Q Growth		 7.19% -7.28% 22.72% 21.23% -10.41% -8.88% 18.49% 3.03% 1.93% -8.93% 23.18%
EPS Q/Q Growth		 7.41% -6.90% 22.22% 21.21% -12.50% -8.57% 18.75% 5.26% 0.00% -7.50% 21.62%
Operating Cash Flow Q/Q Growth		 -22.84% 52.89% -24.37% -60.36% 180.93% -0.75% 70.96% 37.32% -34.32% -28.31% 80.48%
Free Cash Flow Firm Q/Q Growth		 -20.11% -151.09% 19.11% -62.60% -9.19% 41.97% 37.36% 118.69% -136.88% -1,710.86% -8.40%
Invested Capital Q/Q Growth		 10.81% 37.24% 7.48% 20.05% 6.51% 4.59% 0.46% 1.85% 9.06% 14.86% 3.98%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 75.49% 75.74% 75.55% 77.78% 76.86% 76.07% 78.14% 77.44% 76.13% 76.08% 78.17%
EBITDA Margin		 26.98% 29.29% 34.01% 39.98% 33.73% 31.08% 36.08% 36.10% 33.73% 31.47% 36.92%
Operating Margin		 28.62% 25.89% 30.77% 35.78% 29.57% 26.98% 31.39% 31.59% 29.91% 27.84% 33.26%
EBIT Margin		 31.65% 28.11% 32.85% 38.83% 32.56% 29.80% 34.97% 35.02% 32.72% 30.47% 35.90%
Profit (Net Income) Margin		 24.72% 22.01% 25.91% 30.70% 26.01% 23.51% 27.34% 27.55% 26.54% 24.03% 28.29%
Tax Burden Percent		 78.10% 78.31% 78.89% 79.07% 79.90% 78.89% 78.18% 78.67% 81.12% 78.84% 78.80%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 21.90% 21.69% 21.11% 20.93% 20.10% 21.11% 21.82% 21.33% 18.88% 21.16% 21.20%
Return on Invested Capital (ROIC)		 93.87% 69.05% 78.74% 84.83% 68.31% 54.83% 62.78% 59.53% 55.36% 46.65% 56.18%
ROIC Less NNEP Spread (ROIC-NNEP)		 93.29% 68.48% 78.20% 84.06% 67.47% 53.94% 61.72% 58.53% 54.42% 45.80% 55.34%
Return on Net Nonoperating Assets (RNNOA)		 -77.05% -50.58% -56.80% -59.60% -46.39% -33.75% -39.17% -36.47% -32.33% -26.31% -32.30%
Return on Equity (ROE)		 16.82% 18.47% 21.94% 25.24% 21.92% 21.07% 23.61% 23.06% 23.02% 20.34% 23.88%
Cash Return on Invested Capital (CROIC)		 50.03% 18.52% 23.18% 6.67% 8.49% 26.72% 33.05% 43.45% 38.78% 26.05% 24.08%
Operating Return on Assets (OROA)		 20.03% 21.45% 25.03% 29.29% 24.03% 24.65% 28.35% 27.50% 25.16% 24.14% 28.38%
Return on Assets (ROA)		 15.65% 16.79% 19.75% 23.16% 19.20% 19.45% 22.17% 21.63% 20.41% 19.03% 22.37%
Return on Common Equity (ROCE)		 16.82% 18.47% 21.94% 25.24% 21.92% 21.07% 23.61% 23.06% 23.02% 20.34% 23.88%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 21.37% 21.29% 21.90% 0.00% 23.55% 23.40% 22.33% 0.00% 21.97% 0.00%
Net Operating Profit after Tax (NOPAT)		 3.32 3.14 3.92 4.67 4.12 3.75 4.40 4.55 4.71 4.28 5.35
NOPAT Margin		 22.35% 20.28% 24.27% 28.29% 23.62% 21.29% 24.54% 24.85% 24.27% 21.95% 26.21%
Net Nonoperating Expense Percent (NNEP)		 0.58% 0.57% 0.54% 0.78% 0.84% 0.89% 1.06% 1.01% 0.94% 0.85% 0.84%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - 5.77% - - - 5.42% 4.76% 5.67%
Cost of Revenue to Revenue		 24.51% 24.26% 24.45% 22.22% 23.14% 23.93% 21.86% 22.56% 23.87% 23.92% 21.83%
SG&A Expenses to Revenue		 18.14% 25.33% 20.54% 21.90% 24.49% 22.68% 22.90% 21.65% 19.98% 23.63% 20.97%
R&D to Revenue		 4.07% 19.39% 5.96% 2.74% -8.91% 21.75% 4.47% 3.49% -12.56% 3.20% 4.30%
Operating Expenses to Revenue		 46.87% 49.85% 44.78% 42.00% 47.29% 49.09% 46.75% 45.85% 46.21% 48.24% 44.92%
Earnings before Interest and Taxes (EBIT)		 4.70 4.35 5.30 6.41 5.68 5.24 6.27 6.42 6.34 5.95 7.33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 4.01 4.53 5.49 6.60 5.89 5.47 6.47 6.62 6.54 6.14 7.53
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.59 7.54 8.53 7.34 8.27 7.27 6.96 7.64 8.00 7.41 8.06
Price to Tangible Book Value (P/TBV)		 4.72 7.81 8.84 7.60 8.58 7.53 7.21 7.91 8.30 7.69 8.36
Price to Revenue (P/Rev)		 6.34 8.60 9.84 8.70 9.01 8.17 7.98 8.94 9.49 8.88 9.79
Price to Earnings (P/E)		 26.33 35.30 40.10 33.54 34.37 30.87 29.75 34.21 36.13 33.73 36.80
Dividend Yield		 3.72% 2.72% 2.25% 2.42% 3.26% 3.50% 1.44% 1.55% 1.70% 1.18% 1.07%
Earnings Yield		 3.80% 2.83% 2.49% 2.98% 2.91% 3.24% 3.36% 2.92% 2.77% 2.97% 2.72%
Enterprise Value to Invested Capital (EV/IC)		 17.81 20.52 23.43 18.00 18.26 16.39 16.25 18.46 18.58 15.53 17.12
Enterprise Value to Revenue (EV/Rev)		 5.25 7.84 9.07 7.95 8.25 7.51 7.28 8.21 8.78 8.21 9.11
Enterprise Value to EBITDA (EV/EBITDA)		 16.61 24.74 29.04 24.28 24.04 21.68 20.72 23.95 25.61 23.95 26.36
Enterprise Value to EBIT (EV/EBIT)		 17.30 25.33 29.21 24.13 24.89 22.45 21.44 24.79 26.48 24.70 27.16
Enterprise Value to NOPAT (EV/NOPAT)		 22.59 33.96 39.60 33.30 34.15 30.88 29.88 34.80 36.93 34.39 37.44
Enterprise Value to Operating Cash Flow (EV/OCF)		 27.87 33.37 35.88 39.78 40.18 40.00 31.97 24.86 25.08 23.70 26.06
Enterprise Value to Free Cash Flow (EV/FCFF)		 44.07 144.13 126.94 357.68 281.19 72.36 56.38 45.27 51.61 66.98 81.09
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.83 -0.74 -0.73 -0.71 -0.69 -0.63 -0.63 -0.62 -0.59 -0.57 -0.58
Leverage Ratio		 1.15 1.17 1.17 1.16 1.22 1.17 1.15 1.15 1.20 1.14 1.13
Compound Leverage Factor		 1.15 1.17 1.17 1.16 1.22 1.17 1.15 1.15 1.20 1.14 1.13
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 19.66 28.31 30.95 28.19 19.45 30.51 35.04 37.97 38.82 36.83 40.11
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.06 9.07 8.71 9.13 4.65 9.44 9.87 9.21 8.84 8.87 8.78
Quick Ratio		 8.33 8.04 7.50 7.55 3.80 7.64 8.11 7.70 7.38 7.44 7.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.72 -6.82 -5.52 -8.97 -9.80 -5.69 -3.56 0.67 -0.25 -4.45 -4.82
Operating Cash Flow to CapEx		 644.27% 70.86% 928.79% 317.22% 618.27% 811.01% 522.81% 227.24% 195.87% 109.57% 274.33%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.63 0.76 0.76 0.75 0.74 0.83 0.81 0.79 0.77 0.79 0.79
Accounts Receivable Turnover		 5.79 6.26 6.15 5.37 5.14 5.51 6.03 6.16 6.43 5.84 6.79
Inventory Turnover		 2.49 2.41 2.14 1.77 1.69 1.67 1.55 1.42 1.45 1.49 1.54
Fixed Asset Turnover		 23.85 10.46 10.93 11.27 11.22 7.48 7.24 6.19 5.61 5.04 4.65
Accounts Payable Turnover		 9.31 8.88 8.42 8.01 8.43 10.43 8.62 7.79 9.00 8.95 11.84
Days Sales Outstanding (DSO)		 63.04 58.32 59.33 67.91 70.98 66.22 60.50 59.25 56.76 62.49 53.77
Days Inventory Outstanding (DIO)		 146.80 151.44 170.51 205.64 215.51 218.72 236.09 256.56 250.90 244.59 237.47
Days Payable Outstanding (DPO)		 39.20 41.11 43.35 45.57 43.32 35.00 42.33 46.83 40.55 40.77 30.84
Cash Conversion Cycle (CCC)		 170.63 168.66 186.49 227.99 243.17 249.94 254.26 268.98 267.11 266.31 260.40
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 16 22 23 28 30 31 31 32 35 40 41
Invested Capital Turnover		 4.20 3.41 3.24 3.00 2.89 2.58 2.56 2.40 2.28 2.13 2.14
Increase / (Decrease) in Invested Capital		 6.04 9.96 9.43 14 14 9.43 7.96 3.89 4.95 8.73 10
Enterprise Value (EV)		 280 443 543 501 541 508 506 585 643 617 707
Market Capitalization		 338 485 589 548 591 553 555 637 695 667 760
Book Value per Share		 $5.86 $5.11 $5.48 $5.92 $5.67 $6.01 $6.29 $6.59 $6.85 $7.08 $7.42
Tangible Book Value per Share		 $5.70 $4.93 $5.29 $5.72 $5.47 $5.80 $6.07 $6.36 $6.61 $6.83 $7.15
Total Capital		 74 64 69 75 71 76 80 83 87 90 94
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -58 -43 -46 -47 -50 -45 -49 -52 -52 -50 -53
Capital Expenditures (CapEx)		 0.47 6.56 0.38 0.44 0.63 0.48 1.27 4.01 3.06 3.92 2.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 11 12 13 17 9.91 19 18 15 14 16 16
Debt-free Net Working Capital (DFNWC)		 69 55 59 64 60 64 66 66 67 67 69
Net Working Capital (NWC)		 69 55 59 64 60 64 66 66 67 67 69
Net Nonoperating Expense (NNE)		 -0.35 -0.27 -0.26 -0.40 -0.42 -0.39 -0.50 -0.50 -0.44 -0.41 -0.42
Net Nonoperating Obligations (NNO)		 -58 -43 -46 -47 -42 -45 -49 -52 -52 -50 -53
Total Depreciation and Amortization (D&A)		 -0.69 0.18 0.19 0.19 0.21 0.23 0.20 0.20 0.19 0.19 0.21
Debt-free, Cash-free Net Working Capital to Revenue		 20.59% 20.84% 21.18% 27.48% 15.12% 28.28% 25.31% 20.34% 19.79% 21.73% 20.05%
Debt-free Net Working Capital to Revenue		 129.33% 96.59% 97.71% 101.71% 91.02% 94.95% 95.16% 92.87% 91.11% 88.70% 88.31%
Net Working Capital to Revenue		 129.33% 96.59% 97.71% 101.71% 91.02% 94.95% 95.16% 92.87% 91.11% 88.70% 88.31%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.29 $0.27 $0.33 $0.40 $0.36 $0.33 $0.39 $0.40 $0.40 $0.37 $0.45
Adjusted Weighted Average Basic Shares Outstanding		 12.56M 12.59M 12.60M 12.60M 12.60M 12.66M 12.66M 12.67M 12.67M 12.71M 12.72M
Adjusted Diluted Earnings per Share		 $0.29 $0.27 $0.33 $0.40 $0.35 $0.32 $0.38 $0.40 $0.40 $0.37 $0.45
Adjusted Weighted Average Diluted Shares Outstanding		 12.64M 12.69M 12.72M 12.74M 12.72M 12.75M 12.76M 12.78M 12.78M 12.83M 12.84M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 12.59M 12.59M 12.60M 12.61M 12.66M 12.66M 12.67M 12.67M 12.72M 12.72M 12.72M
Normalized Net Operating Profit after Tax (NOPAT)		 3.32 3.14 3.92 4.67 4.12 3.75 4.40 4.55 4.71 4.28 5.35
Normalized NOPAT Margin		 22.35% 20.28% 24.27% 28.29% 23.62% 21.29% 24.54% 24.85% 24.27% 21.95% 26.21%
Pre Tax Income Margin		 31.65% 28.11% 32.85% 38.83% 32.56% 29.80% 34.97% 35.02% 32.72% 30.47% 35.90%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 97.90% 96.18% 90.03% 80.99% 76.91% 44.50% 52.97% 63.22% 71.11% 39.74% 39.33%
Augmented Payout Ratio		 97.90% 96.18% 90.03% 80.99% 76.91% 44.50% 52.97% 63.22% 71.11% 39.74% 39.33%

Key Financial Trends

iRadimed (NASDAQ: IRMD) has demonstrated steady financial performance and growth across the last few years through Q2 2025. Below is a summary of key financial highlights and trends observed from its quarterly financial statements covering income, cash flow, and balance sheet data from Q2 2022 through Q2 2025.

  • Revenue Growth: Operating revenue increased from $12.7M in Q2 2022 to $20.4M in Q2 2025, reflecting consistent top-line growth over the three-year period.
  • Net Income Improvement: Net income rose from $3.2M in Q2 2022 to $5.8M in Q2 2025, indicating improving profitability alongside higher revenues.
  • Stable Earnings Per Share (EPS): Basic and diluted EPS increased from approximately $0.26 in Q2 2022 to $0.45 by Q2 2025, showing improved returns for shareholders.
  • Strong Cash from Operations: Net cash from continuing operating activities increased from $1.64M in Q2 2022 to $7.75M in Q2 2025, evidencing stronger operational cash flow generation.
  • Growing Asset Base: Total assets increased from approximately $75.7M in Q1 2023 to roughly $106.4M in Q2 2025, supporting business expansion.
  • Increased Cash & Equivalents: Cash balances rose from about $42.8M in Q1 2023 to $53.0M in Q1 2025 and further to $52.9M in Q2 2025, indicating good liquidity maintained over time.
  • Stable Share Count: Weighted average shares outstanding remained fairly consistent around 12.5M - 13M, showing no significant dilution.
  • Consistent Marketing and SG&A Expenses: These operating expenses have fluctuated but generally remained a significant portion of operating expenses, implying steady investment in growth-related activities.
  • Dividend Payouts: Payments of dividends have been consistently significant each quarter (about $2.1M in recent quarters), which while positive for income investors, reduces cash available for reinvestment.
  • Capital Expenditures: Capital spending on property, plant, and equipment has been substantial and somewhat variable but remains a drain on cash flow, e.g., $2.8M in Q2 2025 and higher in earlier quarters.

Summary: iRadimed has shown strong and consistent revenue and profit growth over the past three years, with improving bottom-line metrics and robust operational cash flows. The company maintains a solid liquidity position and a stable capital structure. However, high dividend payouts and capital expenditures could constrain near-term free cash flow despite healthy earnings growth. Investors may view the stable EPS growth and increasing cash from operations as positive signals of underlying business health.

08/29/25 01:08 PM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About iRadimed's Financials

When does iRadimed's fiscal year end?

According to the most recent income statement we have on file, iRadimed's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has iRadimed's net income changed over the last 10 years?

iRadimed's net income appears to be on an upward trend, with a most recent value of $19.23 million in 2024, rising from $2.05 million in 2014. The previous period was $17.19 million in 2023. See iRadimed's forecast for analyst expectations on what’s next for the company.

What is iRadimed's operating income?
iRadimed's total operating income in 2024 was $21.96 million, based on the following breakdown:
  • Total Gross Profit: $56.35 million
  • Total Operating Expenses: $34.39 million
How has iRadimed's revenue changed over the last 10 years?

Over the last 10 years, iRadimed's total revenue changed from $15.65 million in 2014 to $73.24 million in 2024, a change of 367.9%.

How much debt does iRadimed have?

iRadimed's total liabilities were at $11.51 million at the end of 2024, a 44.5% decrease from 2023, and a 375.7% increase since 2014.

How much cash does iRadimed have?

In the past 10 years, iRadimed's cash and equivalents has ranged from $9.45 million in 2014 to $62.00 million in 2021, and is currently $52.23 million as of their latest financial filing in 2024.

How has iRadimed's book value per share changed over the last 10 years?

Over the last 10 years, iRadimed's book value per share changed from 1.93 in 2014 to 6.85 in 2024, a change of 254.6%.


Related Companies

This page (NASDAQ:IRMD) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...
Brownstone Research | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...
Crypto 101 Media | Sponsoredtc pixel